In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
EMPOWER Laser Portfolio Is Unveiled and Featured in Hands-On Session; New Line Features Full Range of Lithotripsy Modes Including Dusting, Stone Stabilization and Soft Tissue
Nearly 1,500 nonprofit and association leaders, professionals and partners attend Xperience 2018 in Orlando, Florida, where Community Brands presented its first Innovation Awards, and shared its corporate vision, solution roadmaps, industry education, product training and importance of working to change the world--everywhere--for the better through technology
Conference in McLean, Virginia to Focus on Global Market Conditions, A&D Industry Consolidation, The Supply Chain View, Program and Technology Leadership, Distribution and more.
- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO
- Data highlights continued investigation of LENVIMA as monotherapy and in combination with Merck's KEYTRUDA across multiple cancer types under global collaboration to co-develop and co-commercialize LENVIMA
- Clinical research to be presented from Bayer's growing oncology portfolio, including radium Ra 223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds
- Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation of PD-(L)1 refractory NSCLC patients with high levels of peripheral blood monocytes; 29% ORR and 5.4 months PFS observed in subpopulation -
EclecticIQ and Pink Elephant partner to bring leading Cyber Threat Intelligence to the South African cyber security community. The first step in this partnership will be a joint presence at the IT Web Security Summit Johannesburg on May 22-23, where EclecticIQ's product portfolio will be showcased.
- Updated results from the large ongoing phase 1 study of DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in metastatic breast cancer, gastric cancer and other tumors with HER2 as cell surface target to be reported
-- Oral Presentations Include Preliminary Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (r/r NHL) and Data from Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Trial of 5F9 in Patients with Advanced Solid Tumors --
First presentation of findings from the ramucirumab REACH-2 study - the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population
Ivanti Recognizes Partners for Outstanding Performance and Significant Contributions as They Help Customers Better Manage and Secure Their Digital Workplaces
Axius, Control4, CUJO, DOMOTZ, Fibaro, Fing, F-Secure, Intel, MMB Networks, Rambus, Trend Micro, VOLANSYS, and Yonomi to discuss IoT support and interoperability at CONNECTIONS™